Innoviva - INVA Stock Forecast, Price & News

3 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for Innoviva in the last year. There are currently 1 sell rating, 1 hold rating and 1 buy rating for the stock. The consensus among Wall Street equities research analysts is that investors should "hold" INVA shares. A hold rating indicates that analysts believe investors should maintain any existing positions they have in INVA, but not buy additional shares or sell existing shares.
View INVA analyst ratings or view top-rated stocks.

3 brokers have issued 12-month price objectives for Innoviva's shares. Their INVA share price forecasts range from $10.00 to $22.50. On average, they expect the company's stock price to reach $15.17 in the next year. This suggests a possible upside of 33.6% from the stock's current price.
View analysts price targets for INVA or view top-rated stocks among Wall Street analysts.

Innoviva's stock was trading at $13.25 at the beginning of the year. Since then, INVA shares have decreased by 14.3% and is now trading at $11.35.
View the best growth stocks for 2023 here.

The company is scheduled to release its next quarterly earnings announcement on Wednesday, April 26th 2023.
View our INVA earnings forecast.

Innoviva, Inc. (NASDAQ:INVA) issued its quarterly earnings results on Wednesday, October, 27th. The biotechnology company reported $0.90 earnings per share (EPS) for the quarter, topping analysts' consensus estimates of $0.43 by $0.47. The biotechnology company had revenue of $97.86 million for the quarter. Innoviva had a trailing twelve-month return on equity of 18.81% and a net margin of 64.56%.

ETFs with the largest weight of Innoviva (NASDAQ:INVA) stock in their portfolio include LeaderShares Activist Leaders ETF (ACTV), ETC 6 Meridian Small Cap Equity ETF (SIXS), Pacer US Small Cap Cash Cows 100 ETF (CALF), SPDR S&P Pharmaceuticals ETF (XPH), Invesco S&P SmallCap Health Care ETF (PSCH), Invesco S&P SmallCap 600 Pure Growth ETF (RZG), Janus Henderson Small Cap Growth Alpha ETF (JSML) and Distillate Small/Mid Cash Flow ETF (DSMC).

Based on aggregate information from My MarketBeat watchlists, some companies that other Innoviva investors own include Inovio Pharmaceuticals (INO), Gilead Sciences (GILD), Exelixis (EXEL), Micron Technology (MU), Advanced Micro Devices (AMD), Pfizer (PFE), Vertex Pharmaceuticals (VRTX), NVIDIA (NVDA), OPKO Health (OPK) and Sorrento Therapeutics (SRNE).

Innoviva trades on the NASDAQ under the ticker symbol "INVA."

Innoviva's stock is owned by a number of retail and institutional investors. Top institutional investors include Renaissance Technologies LLC (6.06%), Dimensional Fund Advisors LP (4.60%), Millennium Management LLC (3.06%), Systematic Financial Management LP (2.80%), Assenagon Asset Management S.A. (2.45%) and LSV Asset Management (2.35%). Insiders that own company stock include George Bickerstaff, Innoviva, Inc, Marianne Zhen, Pavel Raifeld and Plc Glaxosmithkline.
View institutional ownership trends.

Shares of INVA stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

One share of INVA stock can currently be purchased for approximately $11.35.

Innoviva (NASDAQ:INVA) has a market capitalization of $792.00 million and generates $331.34 million in revenue each year. The biotechnology company earns $213.92 million in net income (profit) each year or $2.07 on an earnings per share basis.

Innoviva's mailing address is 1350 OLD BAYSHORE HIGHWAY SUITE 400, BURLINGAME CA, 94010. The official website for the company is www.inva.com. The biotechnology company can be reached via phone at (650) 238-9600, via email at investor.relations@inva.com, or via fax at 650-827-8690.